Press Releases May 28, 2026 08:30 AM

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals to Feature Management at 2026 Jefferies Global Healthcare Conference

By Sofia Navarro LXRX

Lexicon Pharmaceuticals announces that its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference, highlighting the company's ongoing drug development efforts across multiple therapeutic areas including neuropathic pain, hypertrophic cardiomyopathy, obesity, and other cardiometabolic conditions.

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
LXRX

Key Points

  • Lexicon Pharmaceuticals will present at a major healthcare investment conference, providing exposure to investors and analysts.
  • The company is advancing a diverse pipeline with candidates targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, and metabolic disorders.
  • The event will be available live and via replay on the company website, enhancing accessibility for stakeholders.

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.

The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.

About Lexicon Pharmaceuticals    
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.   

For Media Inquiries: 
Dave Belian 
Lexicon Pharmaceuticals, Inc. 
[email protected]  
  
For Investor Inquiries: 
Lisa DeFrancesco 
Lexicon Pharmaceuticals, Inc. 
[email protected] 


Risks

  • Clinical and regulatory risks inherent in drug development could impact future progress and approvals.
  • Market competition in pharmaceuticals and biotechnologies may affect Lexicon's commercial success.
  • Investor sentiment may be tempered if the presentation lacks new or substantial data updates.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026